A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 7-Day Intravenous Infusion in Patients With Advanced Solid Malignancies
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety and Tolerability
Assessed at each visit
David Kerr, MD
Principal Investigator
University of Oxford
United Kingdom: Medicines and Healthcare Products Regulatory Agency
D1531C00003
NCT00497679
August 2006
July 2007
Name | Location |
---|